nwbio.com Open in urlscan Pro
104.198.224.99  Public Scan

Form analysis
1 forms found in the DOM

GET https://nwbio.com/

<form method="get" id="searchform" action="https://nwbio.com/">
  <div class="search-text" id="search-text">
    <input type="text" value="Search..." name="s" id="s" autocomplete="off" data-default="Search...">
  </div>
  <input type="submit" id="searchsubmit" value="">
  <div class="clear"></div>
</form>

Text Content

— Main Menu —HOME DCVAX ® TECHNOLOGY - About DCVax® - Dendritic Cell
Immunotherapy - Patient Stories & Physician Comments PRODUCT CANDIDATES - DCVax®
– L - DCVax® – Direct - DCVax® – Prostate CLINICAL TRIALS - DCVax® – L Phase III
for GBM Brain Cancer - DCVax® – Direct Phase I/II for All Types of Inoperable
Solid Tumor Cancers INVESTORS & MEDIA - Press Releases - SEC Filings - Webcasts
- Board Committee Charters - Code of Conduct - Notice of Proposed Settlement -
Related-Party Transaction Policy - Corporate Governance Guidelines ABOUT US -
Overview - Company Management - Publications - Related Links - Contact Us - -
General Inquiries - - Patient Inquiries

 * HOME
 * DCVAX ® TECHNOLOGY+
   * About DCVax®
   * Dendritic Cell Immunotherapy
   * Patient Stories & Physician Comments
 * PRODUCT CANDIDATES+
   * DCVax® – L
   * DCVax® – Direct
   * DCVax® – Prostate
 * CLINICAL TRIALS+
   * DCVax® – L Phase III for GBM Brain Cancer
   * DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
 * INVESTORS & MEDIA+
   * Press Releases
   * SEC Filings
   * Webcasts
   * Board Committee Charters
   * Code of Conduct
   * Notice of Proposed Settlement
   * Related-Party Transaction Policy
   * Corporate Governance Guidelines
 * ABOUT US+
   * Overview
   * Company Management
   * Publications
   * Related Links
   * Contact Us+
     * General Inquiries
     * Patient Inquiries






> OUR TECHNOLOGY


DCVAX® IS A PLATFORM
TECHNOLOGY THAT USES
ACTIVATED DENDRITIC CELLS


> OUR PRODUCTS


DCVAX® – L
DCVAX® – DIRECT
DCVAX® – PROSTATE






Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused
on the development of personalized cancer vaccines designed to treat a broad
range of solid tumor cancers.

Read more about NW Bio >>




LATEST VIDEOS

CLINICAL TRIAL PROGRAM UPDATE: PRESENTATION BY DR. MARNIX BOSCH AT ASCO 2019


Click on arrows to view full-screen video.
Download Presentation



RECENT PRESENTATIONS & INTERVIEWS

11
DEC
2019


DR. BOSCH’S PRESENTATION AT GBM DRUG DEVELOPMENT SUMMIT IN BOSTON: DCVAX®-L
PHASE III TRIAL, “WHERE ARE WE, AND HOW DID WE GET HERE?”



03
JUN
2019


CLINICAL TRIAL PROGRAM UPDATE: PRESENTATION BY DR. MARNIX BOSCH AT ASCO 2019






PRESS RELEASES

23
AUG
2022


NORTHWEST BIOTHERAPEUTICS ANNOUNCES APPROVAL OF PEDIATRIC INVESTIGATION PLAN
(PIP) BY MHRA: PIP APPROVAL IS A PRE-REQUISITE FOR APPLICATION FOR APPROVAL OF A
NEW MEDICINE FOR ADULT PATIENTS



06
JUL
2022


NORTHWEST BIOTHERAPEUTICS ANNOUNCES FILING OF APPLICATION FOR LICENSE FOR
COMMERCIAL MANUFACTURING AT SAWSTON, UK FACILITY









Follow us On: 
 * DCVAX® TECHNOLOGY
   * About DCVax®
   * Dendritic Cell Immunotherapy
   * Patient Stories & Physician Comments
 * PRODUCT CANDIDATES
   * DCVax® – L
   * DCVax® – Direct
   * DCVax® – Prostate
 * CLINICAL TRIALS
   * Pipeline
   * DCVax® – L Phase III
   * DCVax® – Direct Phase I/II

 * INVESTORS & MEDIA
   * Contacts
   * SEC Filings
   * Stock Information
   * Press Releases
   * Webcasts
 * ABOUT US
   * Overview
   * Company Management
   * Publications
   * Related Links
   * Contact Us

© 2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: 240-497-9024

 * Forward-looking Statement
 * Legal Disclaimer
 * Privacy Policy